Drug Database
CA

cannabidiol + THC (CogniCann)

✓ Approved

Argent BioPharma · CNR1

What is cannabidiol + THC?

cannabidiol + THC is a therapeutic agent developed by Argent BioPharma. It is approved for therapeutic indications via oral (po) or sublingual (sl)/oral transmucosal.

Drug Profile

Brand NamesCogniCann
CompanyArgent BioPharma
Molecular TargetCNR1, CNR2, TRPV1, GPR55
RouteOral (PO), Sublingual (SL)/Oral Transmucosal
StatusApproved
Sources: ClinicalTrials.gov, Argent BioPharma

Mechanism of Action

Molecular Targets

cannabidiol + THC acts on 4 molecular targets:

CNR1cannabinoid receptor 1 (CNR, CB1A)
CNR2cannabinoid receptor 2 (CX5, CB-2)
TRPV1transient receptor potential cation channel subfamily V member 1 (VR1)
GPR55G protein-coupled receptor 55 (LPIR1)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

cannabidiol + THC is developed for 3 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Nervous system disordersDementia✓ Approved
Nervous system disordersDementia Alzheimer's type✓ Approved
Psychiatric disordersAgitationPhase II

Related Research Articles

PubMedFrontiers in immunology2026-10-15

Spatial compartmentalization shapes distinct germinal center states during respiratory viral infection.

Kim Dong-Yeon DY, Woo YoungMin Y, Oh Taehwan T, Kim Green G et al.

Germinal centers (GCs) typically arise within the lymph node cortex, where follicular dendritic cell (FDC) networks and follicular helper T cells coordinate B-cell expansion, affinity maturation, and durable immunity. Whether proliferating B-cell aggregates in the medulla engage bona fide GC programs or instead represent a distinct GC-like differentiation state remains unresolved. In this study, using mediastinal lymph nodes from SARS-CoV-2-infected cynomolgus macaques, we combined immunofluorescence with Xenium spatial transcriptomics to identify LYVE1+ sinus-associated medullary GC structures (mGCs) alongside conventional cortical GCs (cGCs). mGCs shared core GC-associated modules with cGCs but showed niche-divergent features, including increased expression of PRDM1, MZB1, and VWF and decreased expression of IRF8, CD27, and CD86. mGCs retained organized follicular architecture but showed lower CD4+ T and GC B cell densities, greater plasma cell representation, and enrichment of pDCs, NK cells, and stromal populations. Compared with cGCs, mGCs lacked polarized CD35+ FDC and CD3+ T cell network topology, exhibited reduced CXCL12 availability, and showed a higher IgM/IgG ratio. During early reinfection, medullary secondary follicles contracted sharply and were associated with higher Foxp3+ cell density. These findings support a model in which lymph node microanatomy imprints a distinct mGC state, diversifying humoral immune architecture during respiratory viral infection.

PMID 42876739
Read full article →
PubMedBiotechnology journal2026-10-15

An Integrated Transient Expression and UPLC-PDA Approach for Functional Genomics and Metabolic Analysis of Cannabis sativa.

Pullano Sarah S, Shahabi Aida A, Torbaghani Parmis Shariat PS, Monsalvo Ivan I et al.

Cannabis sativa (Cannabis) is a high-value medicinal crop whose functional genomics and metabolic engineering remain constrained by limited genetic tools. The species is regarded as recalcitrant to stable transformation, and existing transient expression systems exhibit low efficiency or are restricted to hemp cultivars. Here, we report two Agrobacterium-mediated agroinfiltration protocols enabling rapid, robust, and reproducible transient gene expression in drug-type, high-THC Cannabis tissues. Using the RUBY betalain reporter system, we demonstrate transformation efficiencies of up to 100% in mature leaf disks and 81%-100% in whole seedlings. By independently comparing Agrobacterium strains and vector configurations, we demonstrate that transformation efficiency and transgene expression are influenced by distinct experimental variables, with EHA105 providing the highest transformation efficiency and p35S-based vectors producing the strongest reporter expression. Complementing these genetic tools, we developed a UPLC-PDA method enabling simultaneous detection and quantification of cannabinoids and cannflavins. While not intended to replace mass spectrometry-based analyses, the method provides an accessible and cost-effective platform for comparative metabolite profiling during functional genomics and metabolic engineering studies. Together, these advances establish an integrated workflow linking high-efficiency transient gene expression with streamlined biochemical analysis, providing a practical foundation for gene function studies, pathway interrogation, and biotechnology-driven trait engineering in Cannabis.

PMID 42875966
Read full article →
PubMedNature communications2026-10-15

Difunctionalization of unsaturated hydrocarbons via EDA complexes to access pentafluorosulfanyl thioethers.

Zhang Xiaofeng X, Jiang Yuanyang Y, Yang Hui-Yi HY, Ma Yifan Y et al.

Recently, the pentafluorosulfanyl (SF5) group has attracted considerable interest from medicinal chemists owing to its capacity to significantly enhance the pharmaceutical properties of small-molecule drug candidates. However, a general method for three-component pentafluorosulfanylation of electron-deficient alkenes remains elusive. Herein, we present an electron donor-acceptor (EDA) complex photoactivation strategy for the thiopentafluorosulfanylation of unsaturated hydrocarbons, including electron-deficient alkenes, alkynes, 1,6-enynes, and even acetylene gas. The utility of this approach is demonstrated through the synthesis of a diverse array of pentafluorosulfanyl thioethers and the late-stage functionalization of complex molecules, including pharmaceuticals, natural products, and amino acid derivatives. This work establishes a framework for designing atom-economical difunctionalization reactions that employ green LEDs under mild conditions. Moreover, mechanistic studies support an EDA complex-mediated pathway and identify ArSCl as a key intermediate formed upon generation of the thiyl radical.

PMID 42875439
Read full article →
PubMedBiotechnology journal2026-10-15

Recent Advances in Engineering Ammonia Lyase for Biosynthesis of Aromatic Noncanonical Amino Acids.

Zhang Wen W, Sun Yu Y, Liao Zhen-Yu ZY, Xue Bin B et al.

Aromatic noncanonical amino acids (aromatic ncAAs) are valuable building blocks for pharmaceuticals, agrochemicals, food additives, and specialty chemicals, yet their sustainable and stereoselective synthesis remains challenging. Ammonia-lyases (ALs) have emerged as powerful biocatalysts for the one-step asymmetric hydroamination of arylacrylic acids, and recent advances in protein engineering have substantially enhanced their catalytic performance including efficiency, selectivity, promiscuity, and productivity. This review integrates catalytic mechanisms with the deployment of engineering strategies to illustrate how aromatic amino acid ammonia-lyases (AALs) have evolved into versatile biocatalysts for aromatic ncAAs synthesis. Particular attention is devoted to the engineering of AALs (including phenylalanine, tyrosine, histidine ammonia lyase) and (methyl)aspartate ammonia lyases, highlighting progress in substrate scope expansion, catalytic promiscuity, selectivity modulation, and hybrid catalytic systems. Current limitations and emerging opportunities are further assessed to delineate future directions for next-generation ALs engineering. The engineering strategies and current states of ALs summarized herein provide a conceptual basis for the efficient development of ALs for sustainable aromatic ncAAs biomanufacturing.

PMID 42875960
Read full article →
PubMedDiabetologia2026-10-15

Efficacy and safety of HRS-7535, a novel oral small-molecule glucagon-like peptide-1 receptor agonist, in participants with type 2 diabetes mellitus inadequately controlled by metformin and sodium-glucose co-transporter 2 inhibitors: a multicentre, randomised, double-blind, placebo-controlled, parallel-group Phase II trial.

Xu Mingtong M, Song Weihong W, Lv Fang F, Fu Yanqin Y et al.

This study aimed to evaluate the efficacy and safety of HRS-7535, an oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1RA), in Chinese participants with type 2 diabetes mellitus inadequately managed by metformin and sodium-glucose co-transporter 2 inhibitors (SGLT2i). This multicentre, randomised, double-blind, placebo-controlled, Phase II study included participants aged 18-75 years with type 2 diabetes, HbA1c 58-97 mmol/mol (7.5-11.0%) and BMI 20.0-35.0 kg/m2 and on stable-dose metformin and sodium-glucose co-transporter 2 (SGLT2) inhibitor therapy for ≥8 weeks prior to screening. Participants were assigned in a 1:1:1 ratio to receive HRS-7535 30 mg, HRS-7535 60 mg or visually matching placebo tablets once daily using a stratified block randomisation method, with treatment assignments concealed until study completion. The primary endpoint was the change in HbA1c from baseline to week 16. Secondary efficacy outcomes included the proportions of participants achieving HbA1c targets of <53 mmol/mol (7.0%) and ≤48 mmol/mol (6.5%), and changes from baseline in fasting body weight to week 16. A total of 155 participants with a mean baseline HbA1c of 69 mmol/mol (8.5%) were randomly assigned to HRS-7535 30 mg (n=51), HRS-7535 60 mg (n=53) or placebo (n=51). At week 16, the least‑squares mean differences in HbA1c from baseline for the HRS-7535 30 mg, HRS-7535 60 mg and placebo groups were -16 mmol/mol (95% CI -19, -14) (-1.5% [95% CI -1.7, -1.3]), -20 mmol/mol (95% CI -22, -17) (-1.8% [95% CI -2.0, -1.6]) and -4 mmol/mol (95% CI -7, -2) (-0.4% [95% CI -0.6, -0.2]), respectively (p<0.0001 for both HRS-7535 doses vs placebo). The proportions of participants achieving HbA1c <53 mmol/mol (7.0%) were 51.0% in the HRS‑7535 30 mg group, 66.0% in the HRS‑7535 60 mg group, and 9.8% in the placebo group; the corresponding proportions for HbA1c ≤48 mmol/mol (6.5%) were 35.3%, 37.7% and 3.9%, respectively. Body weight loss was -2.4% in the HRS-7535 60 mg group vs -0.7% in the placebo group. Most treatment-emergent adverse events (TEAEs) were mild to moderate, and gastrointestinal adverse events were the most common. No severe hypoglycaemia was reported. The only TEAE that led to treatment discontinuation occurred in the placebo group. Treatment with HRS-7535 resulted in significant improvements in glycaemic management in participants with type 2 diabetes, and the drug exhibited a favourable safety profile. To address a significant clinical data void, this research focused on the addition of HRS‑7535 to the background regimen of metformin and SGLT2i for glycaemic management in participants with type 2 diabetes. Trial registration ClinicalTrials.gov NCT06393348. Funding This study was funded by Jiangsu Hengrui Pharmaceuticals.

PMID 42875600
Read full article →
PubMedThe Journal of pharmacology and experimental therapeutics2026-10-14

Antinociceptive interaction of Δ9-tetrahydrocannabinol and cannabidiol in a humanized mouse model of sickle cell disease.

Mabou Tagne Alex A, Ajeigbe Olufunke Florence OF, Avalos Heidi C HC, Galvani Francesca F et al.

Sickle cell disease (SCD) is characterized by recurrent, debilitating pain. Opioid analgesics are routinely used in its management, but limited efficacy and pervasive side effects prompt many patients with SCD to seek alternatives, including cannabis. Prior work has shown that 2 major cannabis constituents, Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD), exert antinociceptive effects in HbSS-BERK mice, a model of SCD. The present study investigated the pharmacological interaction between these 2 agents and characterized the effects associated with repeated coadministration. Fixed-ratio isobolographic analyses demonstrated that Δ9-THC and CBD produced dose-dependent antinociception following acute coadministration. Fixed-ratio isobolographic analyses showed that the experimentally determined median effective dose of the mixture was lower than the theoretical additive dose, but the difference was not statistically significant, supporting an additive antinociceptive interaction. Repeated coadministration maintained antinociceptive efficacy over 14 days and reduced SCD-evoked anxiety-like behavior in one cohort but did not improve recognition-memory deficits. Liquid chromatography-tandem mass spectrometry analyses revealed that repeated coadministration increased plasma CBD concentrations, produced a modest increase in Δ9-THC exposure, and markedly elevated circulating levels of the endocannabinoid 2-arachidonoyl-sn-glycerol. Molecular analyses of spinal cord tissue showed that HbSS-BERK mice exhibited increased oxidative stress (malondialdehyde, MDA) and proinflammatory signaling (interleukin [IL]-1β mRNA), with no change in anti-inflammatory signaling (IL-10 mRNA). Following 14 days of treatment, CBD reduced MDA and IL-1β transcription, whereas Δ9-THC reduced MDA and increased IL-10. Notably, the combination treatment simultaneously reduced oxidative stress, suppressed IL-1β, and enhanced IL-10. Together, these findings demonstrate an additive antinociceptive interaction between Δ9-THC and CBD and sustained efficacy during repeated administration in SCD mice. SIGNIFICANCE STATEMENT: Chronic pain in sickle cell disease remains difficult to treat, and many patients use cannabis despite limited understanding of how its constituents interact to produce analgesia. This study demonstrates that the 2 major phytocannabinoids in cannabis, Δ9-tetrahydrocannabinol and cannabidiol, produce additive antinociceptive effects in a humanized mouse model of sickle cell disease, and their combined efficacy is maintained during repeated administration without detectable tolerance.

PMID 42874273
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about cannabidiol + THC